Search Result

Results for "

gastric+cancer+cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (9) Akt (2) AMPK (2) Antibiotic (1) AP-1 (1) Apoptosis (34) Aurora Kinase (1) Autophagy (5) Bacterial (4) Bcl-2 Family (2) c-Met/HGFR (1) Caspase (4) CCR (2) CDK (1) COX (2) DNA/RNA Synthesis (2) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (1) E1/E2/E3 Enzyme (1) EBV (1) EGFR (5) Endogenous Metabolite (1) ERK (13) Ferroptosis (1) FGFR (3) Fungal (1) Glutathione S-transferase (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (5) HSP (1) IAP (1) Integrin (2) Interleukin Related (2) Isotope-Labeled Compounds (4) mAChR (1) MDM-2/p53 (1) MEK (1) Microtubule/Tubulin (2) MMP (2) mTOR (2) NAMPT (2) NF-κB (1) Oxidative Phosphorylation (1) p38 MAPK (1) PAK (4) Parasite (1) PARP (2) PD-1/PD-L1 (3) PDGFR (5) PERK (1) PI3K (2) PROTACs (2) Ras (1) Reactive Oxygen Species (ROS) (4) Reference Standards (9) RIO Kinase (1) Sodium Channel (1) SRPK (1) STAT (5) Thymidylate Synthase (2) TLK (1) TNF Receptor (1) Topoisomerase (1) Tyrosinase (1) VEGFR (4) Wee1 (1) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (83) Cardiovascular Disease (3) Infection (8) Inflammation/Immunology (20) Neurological Disease (2)
Oligonucleotides:	Aptamers (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-B1037

Salbutamol Maximum Cited Publications 7 Publications Verification Albuterol; AH-3365	Adrenergic Receptor ERK	Inflammation/Immunology Cancer
Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease .

HY-B0360

Rebamipide 5+ Cited Publications OPC12759; Proamipide	COX	Inflammation/Immunology Cancer
Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .

HY-A0059

Nifuratel 3 Publications Verification NF 113; SAP 113; Methylmercadone	Bacterial Parasite Antibiotic Fungal Apoptosis STAT Interleukin Related TNF Receptor	Infection Inflammation/Immunology Cancer
Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases .

HY-108713

Famitinib SHR1020	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .

HY-B0436

Salbutamol hemisulfate Maximum Cited Publications 7 Publications Verification Albuterol hemisulfate; AH-3365 hemisulfate	Adrenergic Receptor ERK	Inflammation/Immunology Cancer
Salbutamol (Albuterol) hemisulfate is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol hemisulfate promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol hemisulfate can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease .

HY-100958

4-DAMP 4 Publications Verification 4-DAMP methiodide	mAChR Apoptosis MMP EGFR Interleukin Related	Inflammation/Immunology Cancer
4-DAMP (4-DAMP methiodide) is a potent and selective antagonist of M3 receptors and also has a high affinity for the closely-related M5 receptors. 4-DAMP combined with 5-Fluorouracil (5-Fu) (HY-90006) could significantly reduce the cell viability and enhance apoptosis in MKN45 and BGC823 gastric cancer cells. 4-DAMP inhibits lipopolysaccharide (LPS)- and tobacco-induced pulmonary inflammation and reduces mucin 5AC (MUC5AC), oligomeric mucus/gel-forming secretion .

HY-N0107

Cyclovirobuxine D 1 Publications Verification	Apoptosis Autophagy mTOR Akt	Cardiovascular Disease
Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .

HY-N2587

Irigenin	Integrin Apoptosis	Cancer
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-108628

SU16f 3 Publications Verification	PDGFR	Cancer
SU16f is a potent and selective PDGFRβ inhibitor with IC₅₀s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, VEGF-R2, FGF-R1, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .

HY-N2510

Myristicin Myristicine	5-HT Receptor EGFR ERK Apoptosis Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc .

HY-103363

SB-328437 3 Publications Verification	CCR Thymidylate Synthase	Inflammation/Immunology Cancer
SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC₅₀ of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .

HY-N4148

Purpureaside C	DNA/RNA Synthesis Apoptosis Bacterial	Infection Inflammation/Immunology Cancer
Purpureaside C, phenolic glycoside, is a minichromosome maintenance complex component 6 (MCM6) inhibitor. Purpureaside C binds to the ATP-pocket of MCM6, suppresses MCM6 protein expression in gastric cancer cells. Purpureaside C suppresses gastric cancer cell growth and induces apoptosis. Purpureaside C exerts antibacterial activity and proinflammatory activity. Purpureaside C can be used for the researches of gastric cancer, bacterial infection and inflammation .

HY-125035

LCH-7749944 5 Publications Verification GNF-PF-2356	PAK Apoptosis	Cancer
LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC₅₀ of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis .

HY-P991588

HLX-22 AC101	EGFR Apoptosis	Cancer
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .

HY-170935

SRSF1-IN-1	SRPK PARP Caspase Apoptosis Autophagy	Cancer
SRSF1-IN-1 is a SRSF1 inhibitor. SRSF1-IN-1 inhibits SRSF1 expression, thereby modulating the splicing of Bcl-x pre-mRNA. SRSF1-IN-1 inhibits the proliferation of various cancer cells. SRSF1-IN-1 induces apoptosis in gastric cancer cells, reduces Bcl-xl expression, and upregulates cleaved PARP and caspase 3. SRSF1-IN-1 induces autophagy and promotes cell death. SRSF1-IN-1 exhibits anti-tumor activity in a mouse gastric cancer xenograft model. SRSF1-IN-1 can be used for the research of various cancers including liver cancer, gastric cancer, breast cancer, colon cancer, glioma, and melanoma .

HY-163985

PROTAC FGFR2 degrader 1	PROTACs FGFR Apoptosis	Cancer
PROTAC FGFR2 degrader 1 (compound N5) is a PROTAC that effectively targets FGFR2 with DC₅₀ of 6.46 nM, the FGFR2 IC₅₀ is 0.08 nM. PROTAC FGFR2 degrader 1 has anti-proliferative activity and highly selective, induces G0/G1 arrest of KATOIII and SNU16 cell cycle and inhibits apoptosis by reducing the activation of p-ERK and p-PLCγ, the downstream proteins of FGFR2. PROTAC FGFR2 degrader 1 inhibits gastric cancer cells remained above 50% at a concentration of 0.17 nM. PROTAC FGFR2 degrader 1 potently inhibits the growth of SNU16 xenograft tumors in mouse model (Structure Note: Pink, FGFR2 activator: HY-18708; Blue, E3 ligase ligand: HY--10984; Black, linker: HY-163989; E3 ligase ligand + linker：HY-163986) .

HY-W357818

Glycinexylidide GX	Sodium Channel ERK MEK NF-κB Drug Metabolite	Cancer
Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local agent that can suppress or relieve pain, that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease .

HY-151480

HP590	STAT Apoptosis	Cancer
HP590 is an orally active, novel and potent STAT3 inhibitor (STAT3 luciferase activity: IC₅₀=27.8 nM; ATP inhibition: IC₅₀=24.7 nM). HP590 shows anti-proliferative activity to gastric cancer cells and induces apoptosis .

HY-149843

LC-MB12	FGFR PROTACs	Cancer
LC-MB12 is an orally active PROTAC compound targets FGFR2 degradation with a DC₅₀ of 11.8 nM. LC-MB12 contains BGJ398 (a FGFR2 inhibitor), PROTAC linker and CRBN.LC-MB12 inhibits FGFR2 signaling in gastric cancer cells and has anti-tumor activity .

HY-B1037S

Salbutamol-d3 Albuterol-d₃; AH-3365-d₃	Isotope-Labeled Compounds ERK Adrenergic Receptor	Inflammation/Immunology Cancer
Salbutamol-d₃ (Albuterol-d₃) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease .

HY-B1037S2

Salbutamol-d9 Albuterol-d₉; AH-3365-d₉	Isotope-Labeled Compounds ERK Adrenergic Receptor	Inflammation/Immunology Cancer
Salbutamol-d₉ (Albuterol-d₉) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease .

HY-151577

STAT3-SH2 domain inhibitor 1	STAT Apoptosis	Cancer
STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a K_d value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .

HY-N5058

Dehydroeffusol	Apoptosis	Cancer
Dehydroeffusol is a phenanthrene from medicinal herb Juncus effuses. Dehydroeffusol inhibits gastric cancer cell growth and tumorigenicity by selectively inducing tumor-suppressive endoplasmic reticulum stress and a moderate apoptosis. It shows very low toxicity .

HY-B1037R

Salbutamol (Standard) Albuterol (Standard); AH-3365 (Standard)	Reference Standards Adrenergic Receptor ERK	Inflammation/Immunology Cancer
Salbutamol (Standard) is the analytical standard of Salbutamol. This product is intended for research and analytical applications. Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .

HY-169131

ALKBH1-IN-3 prodrug	AMPK	Cancer
ALKBH1-IN-4 prodrug (Compound 29E) is a prodrug of a DNA N6-methyladenine demethylase ALKBH1 inhibitor that significantly increases the abundance of 6mA in cells and upregulates the AMPK signaling pathway, thereby inhibiting the viability of gastric cancer cells. ALKBH1-IN-4 prodrug exhibits excellent cellular activity and favorable metabolic exposure in vivo, and holds promise for research in gastric cancer .

HY-153190

W1131 1 Publications Verification	Oxidative Phosphorylation STAT Ferroptosis	Cancer
W1131 is a potent STAT3 inhibitor, triggering ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including IL6-JAK-STAT3 pathway and ferroptosis pathway .

HY-E70290

N-Acetylgalactosaminyltransferase 1 GALNT1	Endogenous Metabolite β-catenin Wnt	Cancer
N-Acetylgalactosaminyltransferase 1 (GALNT1) is a glycosyltransferase that initiates mucin-type O-glycosylation by transferring α-GalNAc from UDP-GalNAc to serine (Ser) or threonine (Thr) residues in proteins. Overexpression of N-Acetylgalactosaminyltransferase 1 in gastric cancer can promote abnormal O-glycosylation of CD44, thereby activating the Wnt/β-catenin signaling pathway and regulating the malignant behavior of gastric cancer cells. Additionally, N-Acetylgalactosaminyltransferase 1 plays a crucial role in cancer growth and metastasis by modifying the O-glycosylation of various glycoproteins, such as mucin (MUC1), osteopontin (OPN), matrix metalloproteinase-14 (MMP14), and integrin α3 .

HY-119748

Sageone	Apoptosis	Infection Cancer
Sageone, a diterpene that can be isolated from Rosmarinus officinalis, is a antiviral and anticancer agent. Sageone induces apoptosis in SNU-1 human gastric cancer cells .

HY-108713A

Famitinib malate SHR1020 malate	VEGFR PDGFR Apoptosis	Cancer
Famitinib (SHR1020) malate, an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib malate induces cell apoptosis. Famitinib malate exerts powerful antitumor activity in human gastric cancer cells and xenografts, it can be used for the research of cancer .

HY-162445

KRASG12D-IN-3	Ras PERK	Cancer
KRASG12D-IN-3 is an orally active KRAS ^G12D inhibitor. KRASG12D-IN-3 inhibits the growth of gastric cancer and pancreatic cancer cells. KRASG12D-IN-3 inhibits the activity of p-ERK in gastric cancer cells. KRASG12D-IN-3 can be used for the research of gastric cancer and pancreatic cancer .

HY-173482

TFAP4/Wnt/β-catenin-IN-1	Wnt β-catenin	Cancer
TFAP4/Wnt/β-catenin-IN-1 (Compound A61) is an orally active TFAP4/Wnt/β-catenin inhibitor. TFAP4/Wnt/β-catenin-IN-1 has significant anticancer activity against a variety of cancer cells (such as gastric cancer, lung cancer, breast cancer, etc.), and has the strongest anticancer activity against MGC-803 gastric cancer cells (IC₅₀: 3.92 μM). TFAP4/Wnt/β-catenin-IN-1 induces apoptosis and cell cycle arrest (S phase) in cancer cells by inhibiting the TFAP4/Wnt/β-catenin signaling pathway. TFAP4/Wnt/β-catenin-IN-1 can be used in the study of gastric cancer .

HY-N12726

Halociline	p38 MAPK MMP	Infection Inflammation/Immunology Cancer
Halociline, a derivative of alkaloids, that can be isolated from the marine fungus Penicillium griseofulvum. Halociline targets MAPK1, MMP-9, and PIK3CA in gastric cancer cells, potentially mediated by diverse pathways including cancer, lipid metabolism, atherosclerosis, and EGFR tyrosine kinase inhibitor resistance. Halociline possesses antimicrobial, antioxidant and biofilm inhibitory activities .

HY-B0436R

Salbutamol hemisulfate (Standard) Albuterol hemisulfate (Standard); AH-3365 hemisulfate (Standard)	Reference Standards Adrenergic Receptor ERK	Inflammation/Immunology Cancer
Salbutamol (Albuterol) hemisulfate (Standard) is the analytical standard of Salbutamol hemisulfate (HY-B0436). This product is intended for research and analytical applications. Salbutamol (Albuterol) hemisulfate is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol hemisulfate promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol hemisulfate can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease.

HY-B1037S3

Salbutamol-d9 acetate Albuterol-d9 acetate; AH-3365-d9 acetate	Isotope-Labeled Compounds ERK Adrenergic Receptor	Inflammation/Immunology Cancer
Salbutamol-d₉ (Albuterol-d₉) acetate is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease .

HY-179520

XSJ151	Topoisomerase DNA/RNA Synthesis MDM-2/p53 Bcl-2 Family	Cancer
XSJ151 is a topoisomerase I inhibitor, stabilizing the DNA-Topo I covalent complex and inducing DNA double-strand breaks. XSJ151-induces DNA damage activates the p53-p21 signaling pathway, specifically regulating the expression of cyclins, leading to G2/M phase cell cycle arrest and disrupting the dynamic homeostasis of Bcl-2 family proteins, thereby triggering apoptosis in gastric cancer cells. XSJ151 can be used for the study of gastric cancer .

HY-160068

2-2(t) aptamer sodium	EGFR	Cancer
2-2(t) aptamer sodium is a 42-nucleotide trimeric complex of aptamer (2-2) targeting ErbB-2. 2-2(t) aptamer sodium inhibits the growth of gastric cancer cells in vitro and in vivo .

HY-124398

GL-1196	PAK	Cancer
GL-1196 is an inhibitor of PAK4. GL-1196 can suppress the proliferation and invasion of gastric cancer cells. GL-1196 inhibits PAK4-mediated signaling pathways. GL-1196 can hinder the proliferation of human gastric cancer cells through suppressing PAK4/c-Src/EGFR/CyclinD1 and CDK4/6. GL-1196 can reduce filamentous pseudopodia formation and induce filamentous pseudopodia formation and promote cell elongation in SGC7901 and BGC823 cells. GL-1196 can be studied in anti-cancer research .

HY-W741940

Evomonoside	Others	Cardiovascular Disease Cancer
Evomonoside is a type of cardiac glycoside compound. Evomonoside exhibits significant in vitro anticancer activity, especially having nanomolar inhibitory concentrations against gastric cancer cell lines. Evomonoside has typical cardiac toxicity risks, including arrhythmias and conduction abnormalities. Evomonoside can be used for research on gastric cancer .

HY-176283

Tubulin/LSD1-IN-1	Microtubule/Tubulin Histone Demethylase Apoptosis Wee1 Bcl-2 Family Caspase	Cancer
Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and LSD1 (IC₅₀ = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells .

HY-176237

Nampt-IN-16	NAMPT Apoptosis	Cancer
Nampt-IN-16 (Compound 9a) is an orally active NAMPT inhibitor with an IC₅₀ of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD ⁺ and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer .

HY-108713R

Famitinib (Standard) SHR1020 (Standard)	Reference Standards VEGFR PDGFR Apoptosis	Cancer
Famitinib (Standard) is the analytical standard of Famitinib. This product is intended for research and analytical applications. Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC₅₀ values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .

HY-155115

LSD1-IN-27 1 Publications Verification	Histone Demethylase PD-1/PD-L1	Cancer
LSD1-IN-27 is an orally active LSD1 inhibitor (IC₅₀: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer .

HY-B0360R

Rebamipide (Standard)	COX Reference Standards	Inflammation/Immunology Cancer
Rebamipide (Standard) is the analytical standard of Rebamipide. This product is intended for research and analytical applications. Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer .

HY-179339

LSD1-IN-46	Histone Demethylase	Cancer
LSD1-IN-46 is a potent and orally active Lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 0.082 μM. LSD1-IN-46 interrupts the β-catenin-mediated transcriptional program, thereby suppressing the stemness of gastric cancer cells. LSD1-IN-46 exhibits strong anti-tumor activity. LSD1-IN-46 can be used for the research of gastric cancer .

HY-N2510R

Myristicin (Standard) Myristicine (Standard)	5-HT Receptor EGFR ERK Reference Standards Apoptosis Bacterial	Infection Neurological Disease Inflammation/Immunology Cancer
Myristicin (Standard) is the analytical standard of Myristicin. This product is intended for research and analytical applications. Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc .

HY-175733

CQ3196	RIO Kinase Apoptosis	Cancer
CQ3196 is an orally active RIOK2 inhibitor with a K_d of 14 nM. CQ3196 effectively inhibits the ATPase activity of RIOK2, with an IC₅₀ value of 72 nM. CQ3196 inhibits cell proliferation and colony formation in gastric cancer cell lines. CQ3196 induces cell apoptosis in HGC-27 and AGS cells. CQ3196 suppresses downstream signal pathway of RIOK2. CQ3196 reduces phosphorylation of mTOR and AKT. CQ3196 modulates ribosome function and protein synthesis. CQ3196 inhibits tumor growth and can be used for gastric cancer invtro and invivo research .

HY-168895

c-Fos-IN-1	AP-1 ERK Apoptosis	Cancer
c-Fos-IN-1 (Compound P16) is a c-Jun inhibitor, and decreases mRNA levels and protein levels of c-Fos. c-Fos-IN-1 also inhibits the phosphorylation activity of ERK and the transcriptional activity of AP-1. c-Fos-IN-1 shows anticancer activity by inhibiting ERK/c-Fos/Jun pathway. c-Fos-IN-1 inhibits the proliferation and migration of gastric cancer cells (IC₅₀: 2.31 μM for MGC-803 cell). c-Fos-IN-1 arrests cell cycle at G2/M phase and induces cancer cell apoptosis. c-Fos-IN-1 inhibits gastric cancer tumor growth .

HY-149213

LSD1/TLK1-IN-1 J54; J3-54	Histone Demethylase TLK Apoptosis PD-1/PD-L1	Cancer
LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC₅₀ of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer .

HY-W395613

TY-011	Aurora Kinase	Cancer
TY-011 is an Aurora A/B kinase inhibitor. TY-011 induces abnormal microtubule-kinetochore attachment, leading to DNA damage and apoptosis (Apoptosis) in human gastric cancer cells, and ultimately inhibits cancer cell proliferation, with an IC₅₀ value ranging from 0.11 to 4.49 μM in human gastric cancer cell lines. TY-011 has potential applications in gastric cancer research .

HY-175542

KB-15	STAT Apoptosis Reactive Oxygen Species (ROS) PARP	Cancer
KB-15 is a STAT3 inhibitor. KB-15 exhibits potent anti-proliferative activity against AGS gastric cancer cells (IC₅₀ = 0.29 μM) and BGC-823 gastric cancer cells (IC₅₀ = 0.65 μM). KB-15 exerts anti-tumor effects by inhibiting STAT3 phosphorylation, downregulating HO-1 expression, and promoting intracellular ROS accumulation. KB-15 induces G0/G1 phase cell cycle arrest and apoptosis, as well as suppresses colony formation and migration of gastric cancer cells. KB-15 demonstrates excellent anti-tumor efficacy in BGC-823 subcutaneous xenograft model. KB-15 can be used for the study of gastric cancer .

Cat. No.	상품명	Type

HY-W357818

Glycinexylidide GX	Biochemical Assay Reagents
Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local agent that can suppress or relieve pain, that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease .

Cat. No.	상품명	Target	Research Area	Image

HY-P991588

HLX-22 AC101	EGFR Apoptosis	Cancer
HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .

HY-P992414

MS17-38	Inhibitory Antibodies	Cancer
MS17-38 is a monoclonal antibody targeting PODXL-v2. MS17-38 binds to a specific conformational epitope of PODXL-v2 on gastric cancer cells, modulates target function, inhibits gastric cancer cell growth and migration, and blocks tumor growth and lung metastasis. MS17-38 can be used for the research of gastric cancer .

Cat. No.	상품명	Chemical Structure

HY-B1037S

Salbutamol-d3

Salbutamol-d₃ (Albuterol-d₃) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease .

HY-B1037S2

Salbutamol-d9

Salbutamol-d₉ (Albuterol-d₉) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease .

HY-B1037S3

Salbutamol-d9 acetate

Salbutamol-d₉ (Albuterol-d₉) acetate is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease .

HY-W707640

Salbutamol-d4
Salbutamol-d₄ (Albuterol-d₄; AH-3365-d₄) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD) .

Cat. No.	상품명		Classification